SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 16, 2003
Curis, Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware |
000-30347 |
04-3505116 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 61 Moulton Street Cambridge, Massachusetts |
02138 | |
| (Address of Principal Executive Offices) |
(Zip Code) |
Registrant’s telephone number, including area code: (617) 503-6500
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events and Required FD Disclosure.
Curis, Inc., a Delaware corporation (“Curis”), is filing this current report on Form 8-K for the purpose of filing with the Securities and Exchange Commission (“SEC”) its press release dated May 16, 2003 announcing that it has reached an agreement to terminate its joint venture with Elan Corporation, PLC and Elan International Services, LTD (the “Termination Agreement”).
A copy of the Termination Agreement dated as of May 16, 2003 between Elan Corporation, PLC, Neuralab Limited, Elan International Services, LTD, Elan Pharma International Limited, Curis, Inc. and Curis Newco, LTD is being filed as Exhibit 10.1 to this Current Report on Form 8-K.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
| Exhibit No. |
Description | |
| 10.1+ |
Termination Agreement, dated May 16, 2003, between Elan Corporation, PLC, Neuralab Limited, Elan International Services, LTD, Elan Pharma International Limited, Curis, Inc. and Curis Newco, LTD. | |
| 99.1 |
Press Release, dated May 16, 2003. |
+ – confidential treatment requested as to certain portions of this exhibit of which portions were separately filed with the SEC.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CURIS, INC. | ||||||
| Date: June 3, 2003 |
By: |
/s/ Daniel R. Passeri | ||||
| Daniel R. Passeri President and Chief Executive Officer | ||||||
3
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 10.1+ |
Termination Agreement, dated May 16, 2003, between Elan Corporation, PLC, Neuralab Limited, Elan International Services, LTD, Elan Pharma International Limited, Curis, Inc. and Curis Newco, LTD. | |
| 99.1 |
Press Release, dated May 16, 2003. |
+ – confidential treatment requested as to certain portions of this exhibit of which portions were separately filed with the SEC.
4